Efektivitas Probiotik sebagai Terapi Tambahan pada Pasien IBS (Irritable Bowel Syndrome): Tinjauan Sistematis Farmakoterapi Modern
DOI:
https://doi.org/10.54082/jupin.1954Kata Kunci:
Mikrobiota Usus, Probiotik, Sindrom Iritasi Usus Besar, Telaah Literatur Sistematis, Terapi tambahanAbstrak
Irritable bowel syndrome (IBS) adalah gangguan fungsional kronis pada saluran cerna yang memiliki prevalensi global sekitar 11%, dengan angka kejadian lebih tinggi pada perempuan. Mekanisme terjadinya IBS bersifat kompleks dan dipengaruhi oleh berbagai faktor, salah satunya adalah ketidakseimbangan mikrobiota usus (disbiosis). Probiotik telah banyak diteliti sebagai terapi tambahan yang berpotensi meredakan gejala IBS melalui mekanisme regulasi flora usus serta peningkatan fungsi mukosa intestinal. Artikel ini bertujuan untuk mengkaji secara sistematis bukti ilmiah terkini mengenai efektivitas probiotik sebagai terapi pendamping pada pasien IBS. Penelitian dilakukan dengan metode Telaah Literatur Sistematik (TLS), menggunakan sumber artikel dari database PubMed, Scopus, ScienceDirect, dan Google Scholar yang diterbitkan dalam kurun waktu 10 tahun terakhir, dengan kata kunci probiotik, mikrobiota usus, dan IBS. Kriteria inklusi mencakup studi klinis pada manusia yang mengevaluasi pengaruh probiotik terhadap gejala IBS, dengan kriteria ekslusi (studi in vitro/hewan yang tidak esensial, tinjauan naratif murni). Hasil kajian menunjukkan bahwa penggunaan probiotik memberikan perbaikan signifikan terhadap nyeri perut, kembung, dan pola buang air besar. Efektivitas probiotik dipengaruhi oleh jenis strain, dosis, serta lama pemberian.
Referensi
Almabruk, B. A., Bajafar, A. A., Mohamed, A. N., Al-Zahrani, S. A., Albishi, N. M., Aljarwan, R., Aljaser, R. A., Alghamdi, L. I., Almutairi, T. S., Alsolami, A. S., & Alghamdi, J. K. (2024). Efficacy of probiotics in the management of irritable bowel syndrome: A systematic review and meta-analysis. Cureus, 16(12), e75954. https://doi.org/10.7759/cureus.75954
Bertuccioli, A., Sisti, D., Lazzerini, N., Palazzi, C. M., Zonzini, G. B., Ragazzini, M., & Belli, A. (2025). Targeted probiotic therapy in irritable bowel syndrome: a clinical evaluation on Clostridium butyricum CBM588 and Bifidobacterium longum W11. Frontiers in Medicine, 12, 1604319. https://doi.org/10.3389/fmed.2025.1604319
Caviglia, G. P., Tucci, A., Pellicano, R., Fagoonee, S., Rosso, C., Abate, M. L., Olivero, A., Armandi, A., Vanni, E., Saracco, G. M., Bugianesi, E., Astegiano, M., & Ribaldone, D. G. (2020). Clinical response and changes of cytokines and zonulin levels in patients with diarrhoea-predominant irritable bowel syndrome treated with Bifidobacterium longum ES1 for 8 or 12 weeks: A preliminary report. Journal of Clinical Medicine, 9(8), 2353. https://doi.org/10.3390/jcm9082353
Chlebicz-Wójcik, A., & Śliżewska, K. (2021). Probiotics, prebiotics, and synbiotics in the irritable bowel syndrome treatment: A review. Biomolecules, 11(8), 1154. https://doi.org/10.3390/biom11081154
Gupta, A. K., & Maity, C. (2021). Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study [CONSORT Compliant]. Medicine, 100(3), e23641. https://doi.org/10.1097/MD.0000000000023641
JanssenDuijghuijsen, L., van den Belt, M., Rijnaarts, I., Vos, P., Guillemet, D., Witteman, B., & de Wit, N. (2024). Acacia fiber or probiotic supplements to relieve gastrointestinal complaints in patients with constipation-predominant IBS: a 4-week randomized double-blinded placebo-controlled intervention trial. European Journal of Nutrition, 63, 1983–1994. https://doi.org/10.1007/s00394-024-03398-8
Kwon, H., Nam, E. H., Kim, H., Jo, H., Bang, W. Y., Lee, M., Shin, H., Kim, D., Kim, J., Kim, H., Lee, J., Jung, Y. H., Yang, J., Won, D. D., & Shin, M. (2024). Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial. Scientific Reports, 14, 22384. https://doi.org/10.1038/s41598-024-72887-x
Lewis, E. D., Antony, J. M., Crowley, D. C., Piano, A., Bhardwaj, R., Tompkins, T. A., & Evans, M. (2020). Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in alleviating symptoms of irritable bowel syndrome (IBS): A randomized, placebo-controlled study. Nutrients, 12(4), 1159. https://doi.org/10.3390/nu12041159
Matsuura, N., Kanayama, M., Watanabe, Y., Yamada, H., Lili, L., & Torii, A. (2024). Effect of personalized prebiotic and probiotic supplements on the symptoms of irritable bowel syndrome: An open-label, single-arm, multicenter clinical trial. Nutrients, 16(19), 3333. https://doi.org/10.3390/nu16193333
McFarland, L. V., Karakan, T., & Karatas, A. (2021). Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine, 41, 101154. https://doi.org/10.1016/j.eclinm.2021.101154
Martoni, C. J., Srivastava, S., & Leyer, G. J. (2020). Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial. Nutrients, 12(2), 363. https://doi.org/10.3390/nu12020363
Seong, G., Lee, S., Min, Y. W., Jang, Y. S., Kim, H. S., Kim, E.-J., Park, S.-Y., Kim, C.-H., & Chang, D. K. (2021). Effect of heat-killed Lactobacillus casei DKGF7 on a rat model of irritable bowel syndrome. Nutrients, 13(2), 568. https://doi.org/10.3390/nu13020568
Skrzydło-Radomańska, B., Prozorow-Król, B., Cichoż-Lach, H., Majsiak, E., Bierła, J. B., Kanarek, E., Sowińska, A., & Cukrowska, B. (2021). The effectiveness and safety of multi-strain probiotic preparation in patients with diarrhea-predominant irritable bowel syndrome: A randomized controlled study. Nutrients, 13(3), 756. https://doi.org/10.3390/nu13030756
Xu, H.-L., Zou, L.-L., Chen, M.-b., Wang, H., Shen, W.-M., Zheng, Q.-H., & Cui, W.-Y. (2021). Efficacy of probiotic adjuvant therapy for irritable bowel syndrome in children: A systematic review and meta-analysis. PLOS ONE, 16(8), e0255160. https://doi.org/10.1371/journal.pone.0255160
Zhang, T., Zhang, C., Zhang, J., Sun, F., & Duan, L. (2022). Efficacy of probiotics for irritable bowel syndrome: A systematic review and network meta-analysis. Frontiers in Cellular and Infection Microbiology, 12, 859967. https://doi.org/10.3389/fcimb.2022.859967
Zhou, C., Fang, X., Xu, J., Gao, J., Zhang, L., Zhao, J., Meng, Y., Zhou, W., Han, X., Bai, Y., Li, Z., & Zou, D. (2020). Bifidobacterium longum alleviates irritable bowel syndrome-related visceral hypersensitivity and microbiota dysbiosis via Paneth cell regulation. Gut Microbes, 12(1), 1782156. https://doi.org/10.1080/19490976.2020.1782156
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2026 Dewi Chyntia, Nur Azizah, Nada Farhah Ramadhani, Sevilia Kaysa Rohmatin, July July
Artikel ini berlisensi Creative Commons Attribution 4.0 International License.
